# Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

> **NCT02077634** · PHASE2 · COMPLETED · sponsor: **Universität des Saarlandes** · enrollment: 68 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** abiraterone acetate + prednisone + LHRH-therapy
- **DRUG:** abiraterone acetate + prednisone

## Key facts

- **NCT ID:** NCT02077634
- **Lead sponsor:** Universität des Saarlandes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2019-04-01
- **Final completion:** 2019-04-01
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077634, "Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02077634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*